Table 4. Survival rates and median survival times.
| Subsets | OTG | LATG | ||||
|---|---|---|---|---|---|---|
| 3-y SR, % (95% CI) | 5-y SR, % (95% CI) | MST, months (IQR) | 3-y SR, % (95% CI) | 5-y SR, % (95% CI) | MST, months (IQR) | |
| All included observations | 70.3 (63.8–76.7) | 53.5 (45.3–61.6) | NR | 75.4 (64.9–85.9) | 61.1 (48.1–74.1) | NR |
| TNM stage | ||||||
| I-II | 94.7 (88.9–100) | 91.2 (81.6–100) | NR | 96.3 (89.2–100) | 90.0 (76.9–100) | NR |
| III | 61.3 (52.7–69.9) | 44.2 (34.2–54.2) | NR | 62.2 (46.5–77.8) | 45.5 (28.5–62.4) | 38.5 (16.4–64.4) |
| Adjuvant chemotherapy | ||||||
| Yes | 77.2 (68.6–85.8) | 60.0 (47.1–72.9) | NR | 85.7 (70.7–100) | 68.8 (46.0–91.5) | NR |
| No | 64.1 (54.8–73.3) | 51.2 (40.6–61.7) | NR | 70.5 (57.0–83.9) | 57.9 (42.2–73.6) | NR |
| Matched observations | 70.3 (59.1–81.5) | 47.8 (33.4–62.3) | NR | 75.4 (64.9–85.9) | 61.1 (48.1–74.1) | NR |
| TNM stage | ||||||
| I-II | 92.3 (82.1–100) | 87.5 (71.3–100) | NR | 96.3 (89.2–100) | 90.0 (76.9–100) | NR |
| III | 54.1 (38.0–70.1) | 27.6 (11.3–43.9) | 38.7 (22.0–56.6) | 62.2 (46.5–77.8) | 45.5 (28.5–62.4) | 38.5 (16.4–64.4) |
| Adjuvant chemotherapy | ||||||
| Yes | 81.8 (65.7–97.9) | 60.0 (29.6–90.4) | NR | 85.7 (70.7–100) | 68.8 (46.0–91.5) | NR |
| No | 64.3 (49.8–78.8) | 44.4 (28.2–60.7) | 38.7 (17.0–59.4) | 70.5 (57.0–83.9) | 57.9 (42.2–73.6) | NR |
Abbreviations: CI, confidence interval; IQR, interquartile range; MST, median survival time; NR, not reached; SR, survival rate.